Amadeus leads £4m investment in PhoreMost

Abcam founder Jonathan Milner, Cambridge Enterprise and business angels also participated in the funding round.

The investment will be used to support the company in finding cost-effective treatments for patient-specific drugs.

Company
PhoreMost has developed a screening platform called SiteSeeker, which identifies ways to treat cancer and other diseases previously thought of as ‘undruggable'. According to the company, while there has been considerable progress in identifying hundreds of underlying genetic causes of cancer and other diseases, most of these issues have yet to be impacted by existing drug delivery technologies.

Alongside its SiteSeeker platform, PhoreMost has experience in developing and screening live cells to identify and validate key disease targets and new candidate therapeutics.

People
Chris Torrance is co-founder and CEO of PhoreMost. Ashok Venkitaraman is also co-founder of PhoreMost. Hermann Hauser of Amadeus has joined PhoreMost's board as part of the transaction.

Advisers
Company – Cooley (Legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Amadeus Capital
• United Kingdom